Brighton Collaboration

Pro vaccine safety organization
(Learn how and when to remove this message)
The Brighton Collaboration
Service Mark of the Brighton Collaboration Foundation
Formation2000 (2000)
TypeNPO
PurposeSafest, effective vaccines based on rigorous science
To enhance the science of vaccine research by providing standardized, validated, and objective methods for continuous monitoring of safety profiles and by assessing benefit-risk ratios. These methods are, in turn, recognized and recommended for use by international regulatory and public health agencies.[1]
HeadquartersBasel, Switzerland
Region served
Worldwide
Official language
English
LeaderJan Bonhoeffer, president
Parent organization
Task Force for Global Health
AffiliationsCoalition for Epidemic Preparedness Innovations
Websitebrightoncollaboration.us

The Brighton Collaboration (BC) is a non-profit global vaccine safety research network based in Basel, Switzerland. It is named after the city in England where the idea was first formulated.[2]

History

The Brighton Collaboration was launched in 2000, although the idea of the collaboration started one year earlier, following a presentation by Bob Chen at an international scientific vaccine conference in Brighton. In his talk, he stressed the need to improve vaccine safety monitoring by developing internationally accepted standards.[3]

Organization

The Brighton Collaboration is a program of the Task Force for Global Health, a 501(c)(3) non-profit organization. It is primarily funded by the Coalition for Epidemic Preparedness Innovations (CEPI), and has received funding from a variety of scientific and public health organizations since its inception.[4]

Non-funding partners of the Collaboration include the Council for International Organizations of Medical Sciences, European Medicines Agency, Food and Drug Administration and the World Health Organization.[4]

References

  1. ^ "EVI and Brighton Collaboration Foundation (BCF) sign Memorandum of Understanding (MoU)". Archived from the original on 2011-10-31. Retrieved 2012-07-17.
  2. ^ Kohl, Katrin S.; Bonhoeffer, Jan; Braun, M. Miles; Chen, Robert T.; Duclos, Philippe; Heijbel, Harald; Heininger, Ulrich; Loupi, Elisabeth; Marcy, S. Michael (February 2005), Henriksen, Kerm; Battles, James B.; Marks, Eric S.; Lewin, David I. (eds.), "The Brighton Collaboration: Creating a Global Standard for Case Definitions (and Guidelines) for Adverse Events Following Immunization", Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology), Advances in Patient Safety, Rockville (MD): Agency for Healthcare Research and Quality (US), PMID 21249832, archived from the original on 2022-12-12, retrieved 2023-07-04
  3. ^ Chen RT (1999). "Vaccine risks: real, perceived and unknown". Vaccine. 17 (Suppl 3): S41-6. doi:10.1016/s0264-410x(99)00292-3. PMID 10559533.
  4. ^ a b "Our Partners". Brighton Collaboration. Archived from the original on 2023-07-04. Retrieved 2023-07-04.
  • v
  • t
  • e
Vaccine safety
Vaccine hesitancy
Disease resurgence
Before 2019
2019
  • v
  • t
  • e
>10,000 confirmed cases
1,000 to 10,000 confirmed cases
<1,000 confirmed cases
Others
Legal
Vaccine safety procedures
Anti-vaxxer media
Controversies
Organizations
Scientists
Anti-vaxxer personalities
Anti-vaxxer organizations
United States of America
United Kingdom
Australia
France
Others
Epidemiology and surveillance
Others


Stub icon

This Switzerland-related article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e